Abstract
Subjective, physiological and behavioral effects of subcutaneously administered hydromorphone (6 mg), naloxone (0.2 mg), buprenorphine (0.2 and 0.3 mg), and two buprenorphine-naloxone combinations (buprenorphine 0.2 mg plus naloxone 0.2 mg and buprenorphine 0.3 mg plus naloxone 0.2 mg) were assessed under double-blind conditions in six opioid-dependent volunteers. Physiologic measures and subject- and observer-rated behavioral responses were measured before dosing and for 120 min after drug administration. Hydromorphone decreased pupil diameter and respiration, increased blood pressure and increased scores on subjective measures indicating opioid-like effects. Buprenorphine given alone had no significant effect on any variable measured. Naloxone given alone produced opioid abstinence-like effects which were measurable on subject- and observer-rated behavioral measures and physiological measures. Buprenorphine in combination with naloxone somewhat attenuated the naloxone-precipitated withdrawal response. Overall, the naloxone-buprenorphine combinations produced effects which were qualitatively similar to the effects of naloxone alone, suggesting a low potential for abuse of the combination product by opioid-dependent individuals.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fraser HF, Van Horn GD, Isbell H (1956) Studies of nalorphine in man. Am J Med Sci 231:1–8
Fraser HF, Van Horn GD, Martin WR, Wolbach AB, Isbell H (1961) Methods for evaluating addiction liability. (A) “Attitude” of opiate addicts toward opiate-like drugs, (B) A short-term “direct” addiction test. J Pharmacol Exp Ther 133:371–387
Griffiths RR, Bigelow GE, Liebson I, Kaliszak JE (1980) Drug preference in humans: double-blind choice comparison of pentobarbital, diazepam and placebo. J Pharmacol Exp Ther 215:649–661
Jasinski DR (1977) Assessment of the abuse potentiality of morphine-like drugs (methods used in man). In: Martin WR (ed) Drug addiction I. Springer, New York, pp 197–258
Jasinski DR, Mansky PA (1972) Evaluation of nalbuphine for abuse potential. Clin Pharmacol Ther 13:78–90
Jasinski DR, Martin WR, Hoeldtke RD (1970) Effects of short-and long-term administration of pentazocine in man. Clin Pharmacol Ther 11:385–403
Jasinski DR, Griffith JD, Pevnick J, Clark SC (1975) Progress report on studies for the clinical pharmacology section of the Addiction Research Center. 37th Annual Meeting, The Committee on Problems of Drug Dependence, National Research Council, National Academy of Sciences, Washington, DC, pp 121–161
Jasinski DR, Pevnick JS, Griffith JD (1978) Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry 35:501–516
Jasinski DR, Henningfield JE, Hickey JE, Johnson RE (1983) Progress report of the NIDA Addiction Research Center, Baltimore, Maryland, 1982. In: Harris LS (ed) Problems of Drug Dependence, 1982, National Institute on Drug Abuse Research Monograph 43, DHHS (ADM) 83–1264. Washington DC, pp 92–98
Kolb L, Himmelsbach CK (1938) Clinical studies of drug addiction, III. A critical review of the withdrawal treatments with method of evaluating abstinence syndromes. Am J Psychiatry 94:759–799
Legros J, Khalili-Varasteh H, Margetts G (1984) Pharmacological study of pentazocine-naloxone combination: interest as a potentially non abusable oral form of pentazocine. Arch Int Pharmacodyn Ther 271:11–21
Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE (1976) The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517–532
McLeod D, Griffiths RR, Bigelow GE, Yingling J (1982) An automated version of the digit symbol substitution test (DSST). Behav Res Methods Instrum 14:463–466
Nutt JG, Jasinski DR (1974) Methadone-naloxone mixtures for use in methadone maintenance programs. Clin Pharmacol Ther 15:156–166
Parwatikar SD, Knowles RR (1973) Methadone-naloxone in combination for the treatment of heroin addicts. Clin Pharmacol Ther 14:941–948
Poklis A (1984) Decline in abuse of pentazocine/tripelennamine (T's and Blues) associated with the addition of naloxone to pentazocine tablets. Drug Alcohol Depend 14:135–140
Rolly G, Poelaert J, Mungroop H, Paelinck H (1986) A combination of buprenorphine and naloxone compared with buprenorphine administered intramuscularly in postoperative patients. J Int Med Res 14:148–152
Senay EC (1985) Clinical experience with T's and B's. Drug Alcohol Depend 14:305–311
Vanacker B, Vandermeersch E, Tomassen J (1986) Comparison of intramuscular buprenorphine and a buprenorphine/naloxone combination in the treatment of post-operative pain. Curr Med Res Opin 10:139–144
Author information
Authors and Affiliations
Additional information
Supported by a grant from Reckitt and Colman Pharmaceutical Division and USPHS Grants DA-00050 and DA-04089 from the National Institute on Drug Abuse
Rights and permissions
About this article
Cite this article
Preston, K.L., Bigelow, G.E. & Liebson, I.A. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology 94, 484–490 (1988). https://doi.org/10.1007/BF00212842
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00212842